Biodesix, Inc. announces that David Brunel, Chief Executive Officer, will present at the 2010 Personalized Medicine Partnerships Conference, Wednesday, February 24th, at 11:00 a.m. eastern time. The conference takes place February 22-24th at the Doubletree Hotel in Philadelphia, PA, and will include presentations by both diagnostic and pharmaceutical companies. Mr. Brunel will provide an overview of the Company’s unique approach to personalized medicine and discuss the key elements for successfully financing personalized medicine companies in today’s economic environment.
Biodesix is a fully integrated molecular diagnostic company developing products that support excellence in clinical decision making and improve patient care. The Company’s goal is to give physicians more information to understand the patient and their disease: understanding the clinically meaningful information contained within each patient’s molecular profile leads to better care and better outcomes. Biodesix has demonstrated leadership in personalizing medicine by introducing VeriStrat®, a proteomic test to help physicians guide treatment for patients with non-small cell lung cancer. The Company’s unique approach is based on ProTS®, proprietary technology which exploits the power of mass spectrometry. ProTS provides the unparalleled ability to render complex data sets comparable and thereby enables the discovery of specific molecular profiles that can be used to better characterize the patient and their disease, leading to more informed treatment decisions. Biodesix collaborates with investigators to address key clinical questions, and partners with biotechnology and pharmaceutical companies for development of companion diagnostics and improved targeting of therapies in clinical trials. For more information on Biodesix, please visit the Company’s website at www.Biodesix.com.